Pre-made Belantamab benchmark antibody ( Whole mAb ADC, anti-TNFRSF17 therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Belantamab biosimilar, Whole mAb ADC, Anti-TNFRSF17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Belantamab mafodotin-blmf injection is used to treat multiple myeloma (a type of bone marrow cancer) in patients whose cancer has come back and who have received at least 4 previous treatments (eg, anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent) that did not work well.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-055-1mg	1mg	4635
GMP-Bios-ab-055-10mg	10mg	Inquiry
GMP-Bios-ab-055-100mg	100mg	Inquiry
GMP-Bios-ab-055-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Belantamab biosimilar, Whole mAb ADC, Anti-TNFRSF17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody
INN Name	Belantamab
Target	TNFRSF17
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	GlaxoSmithKline
Conditions Approved	Multiple myeloma
Conditions Active	na
Conditions Discontinued	na
Development Tech	na